Core Viewpoint - WuXi Biologics and Sinorda Biomedicine have announced a strategic collaboration to develop and manufacture SND006, a novel bispecific antibody aimed at treating inflammatory bowel disease (IBD) and other autoimmune diseases [1][2]. Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics from concept to commercialization [4]. - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore [5]. - As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, with 74 in Phase III and 25 in commercial manufacturing [5]. Collaboration Details - Under the agreement, Sinorda Biomedicine will utilize WuXi Biologics' expertise in biologics development to advance SND006's preclinical studies and clinical supply, expediting the Investigational New Drug (IND) application process [2]. - Sinorda Biomedicine has completed in vitro functional validation studies for SND006 and plans to submit IND applications to the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) in 2026 [2]. Future Prospects - The collaboration aims to expand further into Sinorda Biomedicine's pipeline, which includes multiple integrated projects from molecule discovery to clinical manufacturing [2]. - Both companies believe that this partnership will accelerate the IND filings of innovative biologics, addressing unmet medical needs in autoimmune diseases [3]. Sinorda Biomedicine Overview - Established in 2010, Sinorda Biomedicine focuses on the R&D and industrialization of innovative drugs for digestive tract diseases, tumor immunity, and autoimmune diseases [8][9]. - The company has successfully commercialized its self-developed drug for gastric acid-related diseases and has ongoing clinical research for solid tumor treatments [10].